Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

Condition:   The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Intervention:   Drug: Letermovir Sponsor:   Institute of Hematology & Blood Diseases Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials